Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Clin Neuropharmacol ; 25(5): 251-3, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12410055

RESUMEN

Medications that act on the central nervous system are frequently used in people infected with human immunodeficiency virus (HIV). Actually, drug interactions are an important factor in the treatment of patients with (HIV) infection and because of the complexity of the current drug regimens, clinicians should be trained in order to recognize and manage drug interactions. Herein, we present an HIV infected male admitted for manic behavior and treated with risperidone who developed a profound coma secondary to increased levels of risperidone because of a possible drug interaction with ritonavir and indinavir. Subsequently, we discuss this interaction, rarely described in the literature. Risperidone is a cytochrome P450 (CYP2D6) enzyme substrate and weak inhibitor and a CYP3A4 substrate. Possible interactions with CYP2D6 inhibitors (amiodarone, fluoxetine or ritonavir) and CYP3A4 inhibitors (indinavir and ritonavir) can increase its serum concentrations and produce significant adverse effects. In conclusion, this drug combination should be administered with caution and routinely examined for signs and symptoms of risperidone toxicity. Dosages should be reduced as needed. Finally, we think that in patients taking multiple medications, plasma levels of risperidone should be monitored especially if drug interactions are possible.


Asunto(s)
Antipsicóticos/efectos adversos , Coma/inducido químicamente , Inhibidores de la Proteasa del VIH/efectos adversos , Risperidona/efectos adversos , Ritonavir/efectos adversos , Antipsicóticos/uso terapéutico , Trastorno Bipolar/complicaciones , Trastorno Bipolar/tratamiento farmacológico , Coma/patología , Interacciones Farmacológicas , Infecciones por VIH/complicaciones , Infecciones por VIH/tratamiento farmacológico , Inhibidores de la Proteasa del VIH/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Risperidona/uso terapéutico , Ritonavir/uso terapéutico
3.
Eur J Intern Med ; 19(1): 15-21, 2008 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-18206596

RESUMEN

BACKGROUND: Few attempts have been made to compare bacteremic and non-bacteremic pneumococcal pneumonia, mainly because it is difficult to gain agreement on which cases represent non-bacteremic pneumococcal pneumonia. Recently, an immunochromatographic assay for the detection of Streptococcus pneumoniae urinary antigen has been successfully evaluated for the diagnosis of pneumococcal pneumonia. The aim of our study was to examine and compare clinical and radiological features, risk factors, and outcome associated with bacteremic and non-bacteremic groups. METHODS: A retrospective study (1995-2003) analyzing the clinical records of patients diagnosed with pneumococcal pneumonia in our institution was performed. S. pneumoniae were identified by blood cultures (bacteremic group) and detection of urinary antigen (non-bacteremic group). RESULTS: There were 82 patients (57 bacteremic and 25 non-bacteremic). In seven non-bacteremic cases, another etiology was detected, i.e., Legionella (n=1) and Chlamydia pneumoniae (n=6). Bacteremic patients were significantly younger (p=<0.001), more likely to have liver disease (p=0.028), current smokers (p=0.024), alcohol and intravenous drug abusers (p=0.014 and p<0.001, respectively), and infected with HIV (p<0.001). Non-bacteremic patients were more likely to have congestive heart failure (p=0.004), chronic obstructive pulmonary disease (p=0.033) and to be former smokers (p=0.004). Bacteremic cases needed more prolonged intravenous antibiotic treatment (6 days vs. 4.5 days; p=0.006) than non-bacteremic cases and their length of stay was also longer. CONCLUSION: In our study, smoking was the leading risk factor for pneumococcal pneumonia. However, current smokers have an increased risk of bacteremic forms and former smokers and patients with COPD developed non-bacteremic forms more frequently. Bacteremic patients need more prolonged intravenous antibiotic treatment than non-bacteremic patients.


Asunto(s)
Bacteriemia/diagnóstico , Bacteriemia/microbiología , Neumonía Neumocócica/diagnóstico , Neumonía Neumocócica/microbiología , Streptococcus pneumoniae/aislamiento & purificación , Adulto , Anciano , Anciano de 80 o más Años , Combinación Amoxicilina-Clavulanato de Potasio/uso terapéutico , Antibacterianos/uso terapéutico , Antígenos Bacterianos/orina , Bacteriemia/tratamiento farmacológico , Cefalosporinas/uso terapéutico , Infecciones Comunitarias Adquiridas/diagnóstico , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Infecciones Comunitarias Adquiridas/microbiología , Femenino , Fluoroquinolonas/uso terapéutico , Humanos , Tiempo de Internación , Macrólidos/uso terapéutico , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Neumonía Neumocócica/tratamiento farmacológico , Estudios Retrospectivos , Streptococcus pneumoniae/inmunología , Resultado del Tratamiento
4.
Breast J ; 10(3): 244-6, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-15125753

RESUMEN

The prognosis of HIV infection has improved dramatically since the introduction of highly active antiretroviral therapy (HAART). However, numerous adverse effects and limitations regarding tolerability remain a concern. Lipomastia (pseudogynecomastia), a breast enlargement due to central adiposity, may occur as part of a fat redistribution syndrome which has been associated with HAART regimens and several pathogenic mechanisms have been advocated in its development. Here we report an observational longitudinal study of five patients diagnosed of gynecomastia associated with efavirenz-based HAART regimens. All cases reached successful immunologic and virologic responses to HAART. The delay of appearance of gynecomastia from the beginning of HAART ranged between 4 to 15 months. In all five cases, gynecomastia regressed after efavirenz withdrawal (mean period of 5 months). In summary, we think that HAART induced gynecomastia should be suspected in HIV patients receiving efavirenz-containing regimens. Although pathogenesis is unclear, this study and a review of the English literature implicates two possible mechanisms: (a) immune restoration processes and (b) efavirenz mediated estradiol-like effects.


Asunto(s)
Fármacos Anti-VIH/efectos adversos , Ginecomastia/inducido químicamente , Síndrome de Lipodistrofia Asociada a VIH/inducido químicamente , Oxazinas/efectos adversos , Inhibidores de la Transcriptasa Inversa/efectos adversos , Adulto , Alquinos , Fármacos Anti-VIH/administración & dosificación , Terapia Antirretroviral Altamente Activa/efectos adversos , Benzoxazinas , Ciclopropanos , Femenino , Ginecomastia/diagnóstico , Ginecomastia/metabolismo , Infecciones por VIH/tratamiento farmacológico , Síndrome de Lipodistrofia Asociada a VIH/diagnóstico , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Oxazinas/administración & dosificación , Inhibidores de la Transcriptasa Inversa/administración & dosificación , Factores de Riesgo , Factores de Tiempo
5.
South Med J ; 95(7): 751-2, 2002 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12144082

RESUMEN

Empyema necessitatis is a collection of inflammatory tissue that ruptures spontaneously through a weakness in the chest wail into surrounding soft tissues. Although empyema necessitatis can be caused by a number of infectious agents, mycobacteria are the most frequently implicated. Empyema was a much more common complication of pulmonary tuberculosis in the preantibiotic era than it is today. We describe a 22-year-old man with human immunodeficiency virus (HIV) infection who had tuberculous empyema necessitatis and was successfully treated with surgical debridement and antibiotic therapy.


Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/diagnóstico , Empiema Tuberculoso/diagnóstico , Infecciones Oportunistas Relacionadas con el SIDA/terapia , Adulto , Antituberculosos/uso terapéutico , Líquido del Lavado Bronquioalveolar/microbiología , Terapia Combinada , Desbridamiento , Empiema Tuberculoso/terapia , Humanos , Huésped Inmunocomprometido , Masculino , Mycobacterium tuberculosis/aislamiento & purificación , Tomografía Computarizada por Rayos X
6.
Anaerobe ; 9(2): 87-9, 2003 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16887693

RESUMEN

The black pigmented Gram-negative anaerobes, Porphyromonas species, have been isolated from clinical specimens in cases of central nervous system, dental-oral, pleuropulmonary and genitourinary infections and bacteremia. Herein, we report an unusual case of liver abscess caused by Porphyromonas asaccharolytica that has not been previously reported.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA